Bioethical dimension of the pharmacogenetic research | Tauşer | Revista Romana de Bioetica

0

Bromley C.M., Close S., Cohen N. et al., Designing pharmacogenetic projects in

industry: practical design perspectives from the Industry Pharmacogenomics

Working Group, The Pharmacogenomics Journal, 9, pp. 14-22, 2009

Buchanan A., Califano A., Kahn J., McPherson E., Robertson J. and Brody B.,

Pharmacogenetics: ethical issues and policy options, Kennedy Institute of Ethics J., 12,

, pp. 1–15, 2002

Cook-Deegan R., Chandrasekharan S., Angrist M., The dangers of diagnostic monopolies

(commentary), Nature 458, pp. 405-409, 2009

Gaisser S., Hopkins M.M., The phantom menace of gene patents (commentary), Nature,

, pp. 407-408, 2009

Joly Y., Knoppers B.M., Nguyen M.T., Stored tissue samples: through the

confidentiality maze, The Pharmacogenomics Journal, 5, pp. 2-5, 2005

Kahn J. Race, Pharmacogenomics, and Marketing: Putting BiDil in Context, The

American Journal of Bioethics, 6, 5, pp. 21-23, 2006

Lesko L.J., Woodcock J., Pharmacogenomic-guided drug development: regulatory

perspective, The Pharmacogenomics Journal, 2, pp. 20-24, 2002

Licinio J., Wong M.L., Informed Consent in Pharmacogenomics, The

Pharmacogenomics Journal, 2, pp. 343-351, 2002

Roses A.D., Pharmacogenetics and future drug development and delivery, Lancet, 355,

pp. 1358–1361, 2000

Roses A.D., Pharmacogenetics and the practice of medicine, Nature, 405, pp. 857-865,

June, 2000

Smart A., Martin P., Parker M., Tailored medicine: Whom will it fit? The ethics of

patient and disease stratification, Bioethics, 18, 4, pp. 322-342, 2004

Thomas S.M., Pharmacogenetics: the ethical context, The Pharmacogenomics Journal,

, 4, pp. 239-242, 2001

Vaszar L.T., Rosen G.D., Raffin T.A., Pharmacogenomics and the challenge to privacy,

The Pharmacogenomics Journal, 2, pp. 144-147, 2002

Wertz D.C., Ethical, social and legal issues in pharmacogenomics, The

Pharmacogenomics Journal, 3, pp. 194–196, 2003.